-Flamingo is developing two RNA therapies for cancer: danvatirsen, an antisense oligonucleotide in Phase 2 PEMDA-HN study, and FLM-7523, a MALAT1 inhibitor approaching Phase 1- Dr. Andrew Denker, ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
For presentations scheduled prior to 1:00 PM, please go to the SHED Atrium between 8:00 and 8:30 AM and load your final presentation. For presentations scheduled after 1:00 PM, please go to the SHED ...
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related ...
The MarketWatch News Department was not involved in the creation of this content. IABDM Announces Featured Speaker Dr. Paul Anderson for the 2026 Annual Conference: "Oral Health, Root Canals, and ...
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data ...
The impact of new technologies in the care of patients with breast cancer is at the core of the IMPAKT conference on translational research in breast cancer. Abstract 12O - Molecular subtype of breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results